Patents by Inventor Sylvaine Lafont

Sylvaine Lafont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200270219
    Abstract: The present invention provides crystalline forms of compound of formula (Ia) and processes of making the crystalline forms. Also provided are compositions comprising the crystalline forms and methods of use of the crystalline forms.
    Type: Application
    Filed: March 20, 2020
    Publication date: August 27, 2020
    Applicant: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Roelof Johannes Gorter de Vries, Bruno Baillon, Sylvaine Lafont, Myriam Gay de Saint Michel, Stephane Kozlovic
  • Patent number: 10662163
    Abstract: The present invention provides crystalline forms of compound of formula (Ia) and processes of making the crystalline forms.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 26, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Roelof Johannes Gorter de Vries, Bruno Baillon, Sylvaine Lafont, Myriam Gay de Saint Michel, Stephane Kozlovic
  • Patent number: 10433552
    Abstract: This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine-based chiral phase transfer catalyst. The invention also relates to novel quinine-based phase transfer catalysts and to a toluene solvent form of the isoxazoline compound of the invention.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: October 8, 2019
    Assignee: MERIAL, INC.
    Inventors: Chunhua Yang, Loic Patrick Le Hir de Fallois, Charles Q. Meng, Alan Long, Roelof Johannes Gorter de Vries, Bruno Baillon, Sylvaine Lafont, Myriam Gay de Saint Michel, Stephane Kozlovic
  • Publication number: 20190133129
    Abstract: This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine-based chiral phase transfer catalyst. The invention also relates to novel quinine-based phase transfer catalysts and to a toluene solvent form of the isoxazoline compound of the invention.
    Type: Application
    Filed: November 7, 2018
    Publication date: May 9, 2019
    Applicant: MERIAL INC.
    Inventors: Chunhua Yang, Loic Patrick Le Hir de Fallois, Charles Q. Meng, Alan Long, Roelof Johannes Gorter de Vries, Bruno Baillon, Sylvaine Lafont, Myriam Gay de Saint Michel, Stephane Kozlovic
  • Publication number: 20180354917
    Abstract: The present invention provides crystalline forms of compound of formula (Ia) and processes of making the crystalline forms. Also provided are compositions comprising the crystalline forms and methods of use of the crystalline forms.
    Type: Application
    Filed: April 5, 2018
    Publication date: December 13, 2018
    Applicant: MERIAL INC.
    Inventors: Roelof Johannes Gorter de Vries, Bruno Baillon, Sylvaine Lafont, Myriam Gay de Saint Michel, Stephane Kozlovic
  • Publication number: 20170311601
    Abstract: This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine-based chiral phase transfer catalyst. The invention also relates to novel quinine-based phase transfer catalysts and to a toluene solvent form of the isoxazoline compound of the invention.
    Type: Application
    Filed: April 5, 2017
    Publication date: November 2, 2017
    Applicant: MERIAL INC.
    Inventors: Chunhua Yang, Loic Patrick Le Hir de Fallois, Charles Q. Meng, Alan Long, Roelof Johannes Gorter de Vries, Bruno Baillon, Sylvaine Lafont, Myriam Gay de Saint Michel, Stephane Kozlovic
  • Patent number: 8461312
    Abstract: The invention relates to a method for producing 1,4-benzothiepin-1,1-dioxide derivatives substituted with benzyl groups.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: June 11, 2013
    Assignee: Sanofi
    Inventors: Guenter Billen, Wendelin Frick, John Patrick Larkin, Guy Lemaitre, Francoise Bendetti, Philippe Boffelli, Jean-Yves Godard, Christian Masson, Veronique Crocq, Sylvaine Lafont, Jos Hulshof
  • Publication number: 20110245486
    Abstract: The invention relates to a method for producing 1,4-benzothiepin-1,1-dioxide derivatives substituted with benzyl groups.
    Type: Application
    Filed: April 29, 2009
    Publication date: October 6, 2011
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Guenter Billen, Wendelin Frick, John Patrick Larkin, Guy Lemaitre, Francoise Bendetti, Philippe Boffelli, Jean-Yves Godard, Christian Masson, Veronique Crocq, Sylvaine Lafont, Jos Hulshof
  • Patent number: 6982334
    Abstract: The present invention comprises crystalline forms of 3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, represented by the structure: and as characterized herein by powder X-ray diffraction patterns as form A and form B, processes for preparing form A from the purified amorphous form of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, a processes for preparing form A by heating monohydrated form C of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, a pharmaceutical composition comprising form A, a pharmaceutical composition comprising form A and form B or monohydrated form C, a pharmaceutical composition comprising form A, form B and monohydrated form C, a method for treating a bacterial infection with form A, a method for treating a bacterial infection with form A and form B or monohydrated form C, and a method f
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: January 3, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Jacques Bourget, Marc Antoine Perrin, Serge Mignani, Bernd Janocha, Michel Cheve, Carole Neves, Pascal Billot, Michel Tabart, Sylvaine Lafont
  • Patent number: 6939970
    Abstract: The present invention comprises monohydrated form C of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, represented by the structure and as herein defined by powder X-ray diffraction, processes for preparing monohydrated form C from amorphorous (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid or form A of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, pharmaceutical compositions comprising monohydrated form C, pharmaceutical compositions comprising monohydrated form C and form A or form B of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, pharmaceutical compositions comprising monohydrated form C, form A and form B, methods for treating bacterial infection with monohydrated form C, methods for treating bacterial infection with monohydrated form
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: September 6, 2005
    Assignee: Aventis Pharma S. A.
    Inventors: Jacques Bourget, Marc Antoine Perrin, Bernd Janocha, Carole Neves, Pascal Billot, Sylvaine Lafont
  • Publication number: 20040147751
    Abstract: The present invention comprises crystalline forms of 3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, represented by the structure: 1
    Type: Application
    Filed: December 18, 2003
    Publication date: July 29, 2004
    Applicant: Aventis Pharma S. A.
    Inventors: Jacques Bourget, Marc Antoine Perrin, Serge Mignani, Bernd Janocha, Michel Cheve, Carole Neves, Pascal Billot, Michel Tabart, Sylvaine Lafont
  • Publication number: 20040147554
    Abstract: The present invention comprises monohydrated form C of (3R,4R)-4-[3-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylthio)ethyl]piperidine-3-carboxylic acid, represented by the structure 1
    Type: Application
    Filed: December 18, 2003
    Publication date: July 29, 2004
    Applicant: Aventis Pharms S.A.
    Inventors: Jacques Bourget, Marc Antoine Perrin, Bernd Janocha, Carole Neves, Pascal Billot, Sylvaine Lafont